Bosentan is under clinical development by Retinset and currently in Phase I for Diabetic Retinopathy. According to GlobalData, Phase I drugs for Diabetic Retinopathy have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Bosentan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bosentan (BSL01) is under development for the treatment of retinal neurodegeneration induced by diabetic retinopathy. It is administered as ophthalmic eye-drop and acts by targeting endothelin receptor.
For a complete picture of Bosentan’s drug-specific PTSR and LoA scores, buy the report here.